anti-dysrhythmic administered vaginally to treat the uterine dysrhythmia agents.

A vaginal pharmaceutical composition for reducing or relieving uterine dysrhythmia comprising an anti-dysrhythmic agent treatment at a concentration of 1% to 12.5% ​​by weight and a bioadhesive pharmaceutically acceptable carrier that releases the treating agent over a period of time prolonged after administration, wherein the treatment agent is selected anti-dysrhythmic prilocaine, mepivacaine, bupivacaine, ropivacaine, etidocaine, mexiletine, moricizine, propafenone, flecainide and procainamide.